Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone
Purpose of Review The widespread respiratory disease of virus known as severe acute respiratory syndrome–coronavirus 2019 (SAR-CoV-2) had infected more than 200 countries and caused pandemic and havoc in the world. Recent Findings The genome of the virus was sequenced rapidly to study its mechanism, epidemiology, drugs, and vaccines. Many drugs and vaccines are being studied by researchers to treat and prevent the SARS-CoV-2. Favipiravir and dexamethasone are repurposed drugs which showed therapeutic potential and pharmaceutical efficacy against SARS-CoV-2. Summary The review describes the path of favipiravir and dexamethasone from chemistry to mechanisms of action to combat SARS-CoV-2. In addition, the potential side effects are also summarized to study their potential to control corona virus 2019..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Current pharmacology reports - 7(2021), 2 vom: 18. Feb., Seite 49-54 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sood, Shivani [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Coronavirus 2019 |
| doi: |
10.1007/s40495-021-00253-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR043534929 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR043534929 | ||
| 003 | DE-627 | ||
| 005 | 20230519230059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210318s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40495-021-00253-w |2 doi | |
| 035 | |a (DE-627)SPR043534929 | ||
| 035 | |a (DE-599)SPRs40495-021-00253-w-e | ||
| 035 | |a (SPR)s40495-021-00253-w-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Sood, Shivani |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Purpose of Review The widespread respiratory disease of virus known as severe acute respiratory syndrome–coronavirus 2019 (SAR-CoV-2) had infected more than 200 countries and caused pandemic and havoc in the world. Recent Findings The genome of the virus was sequenced rapidly to study its mechanism, epidemiology, drugs, and vaccines. Many drugs and vaccines are being studied by researchers to treat and prevent the SARS-CoV-2. Favipiravir and dexamethasone are repurposed drugs which showed therapeutic potential and pharmaceutical efficacy against SARS-CoV-2. Summary The review describes the path of favipiravir and dexamethasone from chemistry to mechanisms of action to combat SARS-CoV-2. In addition, the potential side effects are also summarized to study their potential to control corona virus 2019. | ||
| 650 | 4 | |a Severe acute respiratory syndrome |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Coronavirus 2019 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Epidemiology |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Favipiravir |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Dexamethasone |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Bhatia, Gurpreet Kaur |e verfasserin |4 aut | |
| 700 | 1 | |a Seth, Prachi |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Pawan |e verfasserin |4 aut | |
| 700 | 1 | |a Kaur, Jagjit |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Vidisha |e verfasserin |4 aut | |
| 700 | 1 | |a Punia, Sandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Tuli, Hardeep Singh |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmacology reports |d Berlin [u.a.] : Springer, 2015 |g 7(2021), 2 vom: 18. Feb., Seite 49-54 |w (DE-627)SPR036533181 |w (DE-600)2809351-3 |x 2198-641X |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2021 |g number:2 |g day:18 |g month:02 |g pages:49-54 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40495-021-00253-w |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 7 |j 2021 |e 2 |b 18 |c 02 |h 49-54 | ||